Photo credit © Poxel
(Boursier.com) — The biopharmaceutical company Poxel will publish its 2023 annual results at the end of April, initially scheduled for April 9, “taking into account the expected conclusion of a transaction by the end of April”.
Poxel, which has made significant progress in its search for additional financing, aims, by the end of April, to conclude an agreement relating to the monetization of royalties from sales of Twymeeg (Imeglimine) in Japan.
Poxel expects that its financial resources are sufficient to maintain its operations until the finalization of this monetization operationincluding only the tranches already drawn or fully available from the equity financing line set up with IRIS.
The company will communicate its new financial calendar for the month of April 2024, as soon as this operation is finalized.
Remember that the Poxel share price is currently 0.518 euros.
©2024 Boursier.com